Thiopurine Methyltransferase Genotype Testing in Paediatric Patients in South Australia. A Retrospective Audit into Prescribing Practices.Mahindroo S1*, Fletcher J2, Hissaria P3, Hakendorf P4 and Nicholson S4
- *Corresponding Author:
- Mahindroo S
Women’s and Children’s Hospital
SA 5006, Australia
E-mail: [email protected]
Received Date: January 11, 2017; Accepted Date: February 09, 2017; Published Date: February 17, 2017
Citation: Mahindroo S, Fletcher J, Hissaria P, Hakendorf P, Nicholson S (2017) Thiopurine Methyltransferase Genotype Testing in Paediatric Patients in South Australia: A Retrospective Audit into Prescribing Practices. J Pharmacogenomics Pharmacoproteomics 8:167. doi: 10.4172/2153-0645.1000167
Copyright: © 2017 Mahindroo S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Thiopurines are used to treat a number of medical conditions including inflammatory bowel disease, acute lymphoblastic leukemia and severe eczema in children. Pre prescription identification of variant alleles helps reduce thiopurine related adverse events. The aim of the study was to explore the clinical utility of TPMT genotyping in a paediatric population in South Australia, specifically the uptake of testing and whether the results are guiding appropriate dosing of thiopurines in keeping with current established international guidelines.
Methods: A retrospective audit was conducted reviewing all patients below the age of 18 years who underwent TPMT genotyping in South Australia during the 10-year period between January 2004 and January 2014. Data regarding demographics and prescribing practices was collected from the medical records of 260 paediatric patients.
Results: Paediatric gastroenterologists requested 67% of the TPMT genotypes performed. Loss of function alleles were confirmed in almost 9% of cases. There were positive correlations between adverse events and whether the test was used correctly (p 0.011) and with subspecialty unit (p<0.001). Oncology recorded the largest percentage of adverse events 63.5% whilst only comprising 16.5% of the total dataset.
Conclusion: The safest prescribing practice in all groups of patients is to ensure the TPMT gentyope is performed prior to administration and dosing is guided by the results and established guidelines.